Start with the sourcing question, not the category label
A therapeutic-category page can help a trade partner find catalogue entries, but the category is only a navigation aid. It does not establish an approved indication, clinical suitability, interchangeability, prescription classification, market authorization, or availability in a destination market. Those conclusions require product-specific evidence and appropriately qualified review.
The first sourcing step is therefore to define the decision: portfolio mapping, preliminary supplier discovery, pack comparison, documentation review, or a market-specific commercial assessment. With the purpose stated, teams can collect only the fields needed to compare entries consistently and keep unresolved questions visible.
Compare structured catalogue fields carefully
Useful discovery fields include the product name, composition as listed, dosage form, release notation where shown, pack configuration, category, and the organization providing the listing. Each field needs its own verification. Similar names can refer to different strengths or release forms, and a composition summary may not reproduce every detail on a current approved label.
A comparison table should preserve the wording supplied for each entry rather than normalizing important differences away. Abbreviations such as EC or SR can be recorded as catalogue text, but their regulatory and product significance should be confirmed from current documents. The online image can help identify a listing; it should not be used as the sole source for label, storage, authorization, or batch information.
- Product and brand name exactly as listed
- Composition wording and any stated strength
- Dosage form and release notation
- Commercial pack configuration
- Destination market and proposed supply role
- Open questions requiring current documentation
Treat formulation and claims as regulatory questions
CDSCO's New Drugs and Clinical Trials Rules define regulatory concepts that can turn on claims, route, dosage form, combinations, and modified or sustained-release forms. That does not determine the status of any Medoxy catalogue entry. It does show why a buyer should not infer status from a familiar ingredient name or category alone.
For each proposed market, qualified teams should verify the product's current classification, permissions, approved particulars, and supply conditions against applicable law and records. A general catalogue can route the question to the right product, but it cannot answer a jurisdiction-specific regulatory assessment.
Make label and pack review a controlled step
CDSCO publishes the Drugs Rules and amendments on its official portal, including requirements relevant to drug labelling and packing. The current legal text and product-specific approvals should guide the review. A catalogue pack value or photograph may be useful for discovery, but buyers should request the current applicable label or artwork and verify the commercial pack before relying on it.
A controlled review records the version examined, market, language, responsible entity, pack identifiers, storage statement, and any conditions that need clarification. If a difference appears between the website and controlled record, the discrepancy should be resolved before commercial use rather than silently harmonized in a spreadsheet.
Connect catalogue selection to distribution requirements
Once a product entry reaches logistics review, the handling discussion must rely on its current controlled instructions. WHO guidance notes that medical products can face risks throughout purchasing, storage, relabelling, transportation, and distribution. Teams should define responsibility for storage conditions, receipt checks, deviations, returns, and traceability before a shipment is arranged.
This is another reason not to publish a universal storage sentence across unrelated dosage forms. The applicable requirement belongs to the specific product record and supply route. The trade inquiry should ask for that record and confirm whether special transport or monitoring arrangements apply.
Use a staged B2B evaluation
A staged process keeps discovery efficient without lowering the evidence threshold. Stage one identifies potentially relevant catalogue entries. Stage two reconciles product identity and pack. Stage three verifies applicable regulatory and quality documents. Stage four reviews commercial, logistics, complaint, and change-management arrangements. An entry advances only when the open questions needed for that stage are resolved.
Medoxy's gastroenterology division page supports stage-one navigation through current catalogue data. It is intended for healthcare and trade professionals seeking product information, not for diagnosis, prescribing, dispensing, or patient self-selection. Product suitability and lawful supply remain matters for qualified professionals using current evidence.